ReviewPediatric investigation2025
Ocular involvement in newly diagnosed pediatric leukemia: A systematic review and meta-analysis.
Review in Pediatric investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Treatment of leukemic ocular infiltrations with intraarterial chemotherapy in very early mixed relapse of B-cell acute lymphoblastic leukemia.Haematologica · 2026Article
- Letter to the Editor: Eye as a window to disease burden in pediatric acute leukemia.World journal of experimental medicine · 2026Article
- Macular Hemorrhage as the First Manifestation of Leukemia.Diagnostics (Basel, Switzerland) · 2026Article
- Ocular involvement in newly diagnosed pediatric leukemia: A systematic review and meta-analysis.Pediatric investigation · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Ocular involvement in pediatric leukemia is often under-recognized, especially in asymptomatic cases. Prevalence estimates of childhood leukemic ophthalmopathy range from 0.32% to 71%, depending on the study design and population. Objective: To determine the prevalence and describe the nature of ocular involvement in newly diagnosed pediatric leukemia through systematic review and meta-analysis. Methods: A comprehensive search of MEDLINE, Embase, Cochrane, and Web of Science databases was conducted up to July 2024. Studies reporting on ocular involvement at diagnosis in children aged 18 years or younger with leukemia were included. Cases of relapsed disease were excluded as were those receiving concurrent treatment. A random effects meta-analysis using an inverse-variance restricted maximum likelihood approach was performed for prevalence estimates. Results: Fourteen studies involving 2989 pediatric leukemia patients were included. The overall pooled prevalence of ocular involvement at diagnosis was 20.32% (95%CI = 9.88%-33.08%). The prevalence of asymptomatic ocular involvement was higher at 23.90% (95%CI = 10.27%-40.63%) compared to 14.75% (95%CI = 0.00%-45.31%) for symptomatic involvement alone. High heterogeneity ( Interpretation: Ocular involvement in newly diagnosed pediatric leukemia is more common than previously understood, particularly for asymptomatic cases. Current practices of selective ophthalmic assessment may miss a number of early-stage ocular manifestations, emphasizing the need for all newly diagnosed patients to be screened for ophthalmic involvement at the time of diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.